期刊文献+

转化生长因子-β1在他克莫司肾毒性中的作用 被引量:2

Expression of transforming growth factor-β1 in tacrolimus (FK506)- induced nephrotoxicity of rats
原文传递
导出
摘要 目的观察转化生长因子(TGF)-β1在他克莫司大鼠肾毒性中的作用。方法将SD大鼠24只随机分成对照组、CsA组、FKS06组和FKS06+Dil组,用药4周后建立起各组大鼠模型。观察各组大鼠的肾功能,应用免疫组织化学技术检测各组大鼠TGF-β1的表达。结果FKS06组大鼠的血肌酐值为(34.17±4.54)μmol/L,肌酐清除率为(0.58±0.39)ml·min^-1·100g^-1,与对照组比较差异有统计学意义(P〈0.05)。FKS06组TGF—β1的阳性表达率均为100%(6/6),对照组TGF-β1的阳性表达率为16%(1/6),两者差异有统计学意义(P〈0.05)。结论TGF-β1可能介导了FKS06引起的肾毒性。 Objective To study the expression of transforming growth factor-β1 in tacrolimus (FK506) ' induced nephrotoxicity Of rats. Methods Twenty-four Sprague-Dawley male rats were randomly divided into 4 groups: control (n =6) ,CsA.treated in =6) ,FK506-treated (n =6) and FK506 + Dil (n = 6). The rats were treated for 4 weeks to develop CsA-induced nephropathy model and FKS06-induced nephropathy medek Renal function and the expression of transforming growth factor-β1 were observed, Resuits The blood serum creatine and creatlnine cleanrance rate in FK506-treated rats were (34. 17 ± 4.54) μmol/L and (0.58 ± 0.39) ml · min^-1 . 100 g^-1. Compared with the control rats, FK506-treated rats showed deterioration in renal function (P 〈 0.05 ). All of the FK506-treated rats were positive for TGF-β1 in renal tissue (6/6) ,but 16% (1/6) control rats were positive for TGF-β1. There was significant difference in the TGF-β1 expression rate between FK506-treated rats and control rats (P 〈 0; 05). Conclusion TGF-β1 mac be involved in the FK506-induced nephrotoxicitv of rats.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2008年第6期784-785,共2页 Chinese Journal of Experimental Surgery
基金 广东省自然科学基金资助项目(06301011) 广东省医学科学技术研究基金资助项目(B2006123) 广州市医药卫生科技项目(2005-YB-003)
关键词 他克莫司 肾毒性 转化生长因子 表达 Tacrolimus Nephrotoxicity Transforming growth factor Expression
  • 相关文献

参考文献5

二级参考文献28

共引文献45

同被引文献32

  • 1孙巧玲,谌贻璞,芮宏亮.一种新型环孢素A慢性肾毒性大鼠模型的建立[J].中国医学科学院学报,2010,32(2):205-209. 被引量:2
  • 2Zhang XQ,Wang ZW, Fan JW, et al. The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacoki- netics analysis in Chinese adult liver-transplant patients [ J ]. Ther Drug Monit,2012,34 ( 2 ) : 126-133.
  • 3Danielson PB. The cytochrome P450 superfamily : biochemistry, evolu- tion and drug metabolism in humans [ J ]. Curr Drag Metab, 2002,3 (6) :561-597.
  • 4Kuehl P,Zhang J,Lin Y,et al. Sequence diversity in CYP3A promot- ers and characterization of the genetic basis of polymorphic CYP3A5 expression[J]. Nat Genet,2001,27(4) :383-391.
  • 5Rojas LE, Herrero M J, Boso V, et al. Meta-analysis and systematic re- view of the effect of the donor and recipient CYP3A5 6986A > G gen- otype on tacrolimus dose requirements in liver transplantation [ J ]. Pharmacogenet Genom,2013,23(10) :509-517.
  • 6Paine MF,Hart HL,Ludington SS,et al. The human intestinal eyto- chrome P450 "pie"[J]. Drug Metab Dispos ,2006,34 (5) : 880-886.
  • 7Thelen K, Dressman JB. Cytochrome P450-mediated metabolism in the human gut wall [ J ]. J Pharm Pharmaeo1,2009,61 (5) :541-558.
  • 8Galetin A, Hinton LK, Burt H, et al. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs [ J ]. Curt Drug Metab ,2007,8 ( 7 ) :685-693.
  • 9Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of mid- azolam by the human intestine [ J ]. Clin Pharmacol Ther, 1996,60 (1) :14-24.
  • 10Berggren S,Gall C,Wollnitz N, et al. Gene and protein expression of P-glyeoprotein,MRP1, MRP2, and CYP3A4 in the small and large human intestine [J]. Mol Pharmaceut, 2007,4 ( 2 ) : 252 -257.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部